

## Rat IgG Fab Biotin

Catalog # ASR1506


## **Product Information**

Description	RAT IgG F(ab) fragment Biotin conjugated
Conjugate	Biotin
Physical State	Lyophilized
Host Isotype	IgG F(ab)
Buffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Species of Origin	Rat
<b>Reconstitution Volume</b>	1.0 mL
Reconstitution Buffer	Restore with deionized water (or equivalent)
Stabilizer	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Preservative	0.01% (w/v) Sodium Azide

## **Additional Information**

Shipping Condition	Ambient
Purity	This product was prepared from normal serum delipidation, salt fractionation, ion exchange chromatography followed by pepsin digestion and extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-biotin, anti-Rat IgG, anti-Rat IgG F(ab')2 and anti-Rat Serum. No reaction was observed against anti-Rat IgG F(c) or anti-Pepsin.
Storage Condition	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Precautions Note	This product is for research use only and is not intended for therapeutic or diagnostic applications.

## Images



SDS-PAGE of Rat IgG F(ab) Fragment Biotin Conjugated (p/n ASR1506). Lane M: 3 µL Opal Prestained Marker (p/n MB-210-0500). Lane 1: Reduced Rat IgG Whole Molecule (p/n 012-0102). Lane 2: Reduced Rat IgG F(c) Fragment (p/n 012-0103). Lane 3: Reduced Rat IgG F(ab) Fragment Biotin Conjugated (p/n ASR1506). Lane 4: Reduced Rat IgM Whole Molecule (p/n 012-0107). Load: 1 µg of IgG, F(c), F(ab); 1.5 µg of IgM. Predicted/Observed size: IgG at 55 and 25 kDa; F(c) at 25 kDa; F(ab) at 25 kDa; IgM at 78 Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.